Browse drugs

…k sac of zebrafish embryos, followed by systemic treatment with Docetaxel. Tumor burden was quantified using fluorescence microscopy, and…

…palliative ChT-IO with Atezolezumab + Pemetexed + Carboplatin + Denosumab followed by Maintenance Chemo IO with Pemetrexed + Atezolizumab…

…F-β individually, in both FaDu and 4T1 tumor models.Conclusions HCB301 represents a novel therapeutic approach that simultaneously tar…

…23–34.Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cel…

…, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patient…

… hepatocellular carcinoma (HCC) exhibiting varying responses to Atezolizumab plus Bevacizumab (Atezo/Bev), and profiled the tumor ecosystems…

…d.aaf2341Leong JW, Chase JM, Romee R, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity I…

…s (n=7, 47%), nivolumab/ipilimumab (n=3, 20%), atezolizumab and durvalumab (n=2 each, 13%), and cemiplimab and toripalimab (n=1 each, 7%) …

…atezolizumab both as a single treatment and in combination with BNT314. In vivo, combining mPD-L1xmVEGF-A with hEpCAMxm4-1BB delayed o…

…ith multiple lines of immunotherapy (durvalumab, pembrolizumab, atezolizumab).Methods In our single-center retrospective cohort (n=57), prim…

…y and (2) 54 patients from the ATTLAS phase III trial comparing atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP) versus pem…

…s of the tumor microenvironment (TME) and clinical outcome from atezolizumab plus bevacizumab (A+B).We therefore employed a supervised ML al…